An Expanding Nanoparticle Characterisation Business

NanoSight Ltd is excited to announce the completion of a new round of financing which will provide £925,000 to enable the company to expand the business with the development of new products and sales channels in the US market.

NanoSight has just closed almost £1m of investment finance in a month that has seen unprecedented financial turmoil worldwide. It became clear to the company that growth was limited by resource but not by market opportunity. Having successfully weathered the start-up process during the past four years, NanoSight can become more robust with investment in personnel, technical support and development of the underlying technology.

CEO, Jeremy Warren, commented: “I am just delighted to have closed this round at the right price and at a time when finance is becoming so much harder to obtain. Our principal investment opportunities are in development of nextgeneration NanoSight instruments and expansion of our operations in the USA.

“As the scope of our technology deepens, we can provide more and more information in bio-nano applications, where complexity is inherent and multi-parameter analysis addresses these needs. We have existing users directing us towards a range of molecular diagnostics applications, with eventual point-of-care use of NanoSight technology being a credible goal. Success in these areas would increase the market opportunity for NanoSight by orders of magnitude, far beyond that of particle characterisation.

“Our approach using Nanoparticle Tracking Analysis provides nanoscience researchers with powerful information to better design products. The systems we shall produce over the coming year will go much further in the additional independent variables they can measure, and, once again, particle–by-particle.”

Significant participants in this round included Bristol-based funder Rowan-Dartington and London Capital Investment Partners. Rowan-Dartington Chief Executive Jonathan Beatson-Hird, commented: “We believe that NanoSight’s innovative product range will have wide ranging commercial applications in the growing nanoparticle market.”

London Capital Investment Partners Chairman Richard Lesmoir-Gordon, explained: “NanoSight represents opportunity for our partners to gain direct exposure to a ground-breaking science and its commercial applications.”